Publications by authors named "Michelle Frascella"

Claim this Profile
D
Discovery of Fluoroalkenes as Dual Inhibitors of Diacylglycerol Kinases Alpha and Zeta (DGKα/ζ).
Ming Xiang, Shicheng Shi, Shaoqun Qian, Chengtsung Lai, Kelly Federowicz, Michelle Frascella

J Med Chem· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of INCB126503 as a Potent and Selective FGFR2/3 Inhibitor.
Minh H Nguyen, Anlai Wang, Lisa Truong, Ke Zhang, Hai-Fen Ye, Michelle Frascella

ACS Med Chem Lett· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Orally Bioavailable FGFR2/FGFR3 Dual Inhibitors via Structure-Guided Scaffold Repurposing Approach.
Minh H Nguyen, Hai-Fen Ye, Yao Xu, Lisa Truong, April Horsey, Michelle Frascella

ACS Med Chem Lett· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Potent and Selective Inhibitors of Wild-Type and Gatekeeper Mutant Fibroblast Growth Factor Receptor (FGFR) 2/3.
Artem Shvartsbart, Jeremy J Roach, Michael R Witten, Holly Koblish, Jennifer J Harris, Michelle Frascella

J Med Chem· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved efficacy of a next-generation ERT in murine Pompe disease.
Su Xu, Yi Lun, Michelle Frascella, Anadina Garcia, Rebecca Soska

JCI Insight· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glucosylceramide and Glucosylsphingosine Quantitation by Liquid Chromatography-Tandem Mass Spectrometry to Enable In Vivo Preclinical Studies of Neuronopathic Gaucher Disease.
Rick Hamler, Nastry Brignol, Sean W Clark, Sean Morrison, Leo B Dungan, Michelle Frascella

Anal Chem· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Coformulation of a Novel Human α-Galactosidase A With the Pharmacological Chaperone AT1001 Leads to Improved Substrate Reduction in Fabry Mice.
Su Xu, Yi Lun, Nastry Brignol, Rick Hamler, Adriane Schilling, Michelle Frascella

Mol Ther· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The pharmacological chaperone AT2220 increases the specific activity and lysosomal delivery of mutant acid alpha-glucosidase, and promotes glycogen reduction in a transgenic mouse model of Pompe disease.
Richie Khanna, Allan C Powe, Yi Lun, Rebecca Soska, Jessie Feng, Michelle Frascella

PLoS One· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The pharmacological chaperone AT2220 increases recombinant human acid α-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease.
Richie Khanna, John J Flanagan, Jessie Feng, Rebecca Soska, Michelle Frascella

PLoS One· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Co-administration with the pharmacological chaperone AT1001 increases recombinant human α-galactosidase A tissue uptake and improves substrate reduction in Fabry mice.
Elfrida R Benjamin, Richie Khanna, Adriane Schilling, John J Flanagan, Lee J Pellegrino, Michelle Frascella

Mol Ther· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease.
Richie Khanna, Rebecca Soska, Yi Lun, Jessie Feng, Michelle Frascella

Mol Ther· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis